Cataract Patient Articles & Analysis
15 news found
CAMPBELL, CA – August 2, 2022 – Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a modular presbyopia-correcting intraocular lens (IOL), announced today the first close of a $42M Series E financing. ...
“Through EDEN, we consolidate our current product range with regards to high vision performance, based on our strong patients’ feedback. With LUCIDIS, the positioning is totally different: it’s a breakthrough product that provides an extended vision for patients at an affordable price. ...
The final study results demonstrated that canaloplasty and trabeculotomy performed as an implant-free minimally invasive glaucoma surgery (MIGS) using the OMNI® Surgical System in conjunction with cataract surgery significantly reduced unmedicated mean diurnal intraocular pressure (IOP), medication use and daily fluctuations in IOP in patients with open-angle ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, today announced that the first patient has been enrolled in a pivotal clinical trial evaluating the Hydrus Microstent in patients with mild to moderate open-angle ...
“We observed that when many of our GEMINI study patients returned for 12-month diurnal IOP monitoring off all medications, their IOP appeared stable throughout the day. ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, has announced new data from its five-year HORIZON pivotal trial showing that the Hydrus Microstent lowers the rate of visual field loss by 47% versus cataract surgery alone. ...
This data aligns with prior secondary, independent patient research from Johns Hopkins University showing that 56% – 59% of glaucoma patients would accept contact lens to treat their disease if they made glaucoma surgery unnecessary or were more effective than eye drops. ...
One of the most important and noteworthy findings of this study is that, of the patients who went on to receive subsequent invasive surgery in the cataract-surgery-only arm, the majority were those who had what we would consider mild glaucoma at baseline. ...
The study was designed to demonstrate the safety and effectiveness of the Hydrus Microstent for lowering intraocular pressure (IOP) in glaucoma patients undergoing planned cataract surgery. Patients were randomized 2:1 to receive cataract surgery plus the Hydrus Microstent or cataract surgery alone. ...
“We are privileged to be able to collaborate with three ophthalmologists and four optometrists who are so knowledgeable and experienced in how to best care for their patients’ vision care needs,” commented Dan Myers, CEO of Leo Lens Pharma. ...
LayerBio plans to develop OcuRing products for multiple cataract surgery-related indications. OcuRing™ is a novel sustained-release technology designed to deliver therapies to cataract surgery patients, potentially eliminating the need for postoperative topical drops. ...
Led by Cormorant Asset Management, with participation by The Capital Partnership (TCP), AMED Ventures and Shangbay Capital, the financing will be used to continue early clinical experience treating cataract patients and support expansion of Atia Vision’s facility. ...
The study was designed to demonstrate the safety and effectiveness of the Hydrus Microstent for lowering intraocular pressure (IOP) in glaucoma patients undergoing planned cataract surgery. Patients were randomized 2:1 to receive cataract surgery plus the Hydrus Microstent or cataract surgery alone. ...
Ivantis today announced long term results of the Australian cohort of the Global SPECTRUM registry. SPECTRUM is a post market patient registry for the Hydrus® Microstent, a microinvasive glaucoma surgery (MIGS) device to treat patients with open-angle glaucoma in conjunction with cataract surgery or as a stand-alone procedure outside the ...
CAMPBELL, CA – September 11, 2019 – Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a novel modular presbyopia- correcting intraocular lens (IOL), today announced its technology will be featured in presentations at two ophthalmology conferences this week in Paris, France. ...